We've found
8,262 Colorectal Cancer
clinical trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Colorectal Cancer Clinical Trial
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Colorectal Cancer Clinical Trial
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Colon Cancer Clinical Trial
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colon Cancer Clinical Trial
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Status: Enrolling,
Phase
I
Updated: 4/11/2018
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
Status: Enrolling,
Phase
II
Updated: 3/13/2018
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
Status: Enrolling,
Phase
II
Updated: 3/13/2018
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Rectal Cancer Clinical Trial
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
8,262 Colorectal Cancer
clinical trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Updated: 12/31/1969
Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Colorectal Cancer Clinical Trial
Updated: 12/31/1969
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Metastatic Colorectal Cancer Clinical Trial
Updated: 12/31/1969
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Colon Cancer Clinical Trial
Updated: 12/31/1969
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colon Cancer Clinical Trial
Updated: 12/31/1969
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 4/11/2018
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
Status: Enrolling,
Phase
I
Updated: 4/11/2018
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
Updated: 3/13/2018
Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
Status: Enrolling,
Phase
II
Updated: 3/13/2018
Click here to add this to my saved trials
Oncology, Psychiatry / Psychology Clinical Trial
Updated: 3/13/2018
Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
Status: Enrolling,
Phase
II
Updated: 3/13/2018
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Neurology, Oncology Clinical Trial
Updated: 12/31/1969
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Rectal Cancer Clinical Trial
Updated: 12/31/1969
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Updated: 12/31/1969
An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials